Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

The investment case for Zhejiang Huahai, based within the province of Zhejiang, is that it is cheap based on current ...

Luckily, the hiring process proceeded smoothly and Charles van Zyl joined as chief executive from Belgian pharma company UCB (BE:UCB) in 2023, while Joerg Hornstein has been in post as chief finance ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

To get a sense of who is truly in control of Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ), it is important to understand the ownership structure of the business. With 66% stake, institutions ...

We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...

Strides Pharma Science is well on track to achieve the FY25 outlook of $275 million-$290 million, post-demerger.

Positive vibes on the broader market indices have kept their upward momentum on the last day of January expiry, with gains ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teva ...